BHE Q4 2025: Medical and ACNC Surge 20%+, Setting Up Early Semi-Cap Recovery
Benchmark Electronics (BHE) capped 2025 with a decisive sector rotation, as medical and ACNC revenues surged over 20% year-over-year in Q4, offsetting softness in semi-cap and industrial. Margin discipline and accelerating bookings in high-growth verticals signal a business model pivoting toward higher-value, less commoditized segments. Management transition and early semi-cap recovery visibility frame 2026 as a year of operational leverage and strategic rebalancing.
Summary
- Sector Rotation Drives Mix Shift: Medical and ACNC rebounded sharply, boosting margin resilience.
- Operational Discipline Unlocks Leverage: Cost control and working capital gains improved cash generation.
- 2026 Visibility Broadens: Early semi-cap recovery and program ramps set up multi-segment growth.
Business Overview
Benchmark Electronics (BHE) is an electronics manufacturing services (EMS) provider focused on complex, high-mix, low-volume solutions across five core sectors: semi-cap (semiconductor capital equipment), industrial, aerospace & defense (A&D), medical, and ACNC (advanced computing & communications). The company generates revenue by designing, engineering, and manufacturing mission-critical products for OEM customers, with a strategic emphasis on high-value, less commoditized markets. Each sector contributes a balanced share to the portfolio, with medical, A&D, and semi-cap as key growth engines.
Performance Analysis
BHE’s Q4 2025 results highlighted a strong finish driven by a decisive mix shift toward medical and ACNC, both delivering over 20% year-over-year growth in the quarter. These segments offset continued softness in semi-cap, which declined 14% YoY, and a flat industrial sector. The company’s balanced approach enabled it to deliver gross margin above 10% for the quarter, with operating margin expanding sequentially and YoY, reflecting improved scale and cost discipline.
Full-year results were flat on the top line but demonstrated sequential momentum, as H2 outpaced H1 and margin expansion outstripped revenue growth. Free cash flow finished at the high end of the target range, supported by a 22-day YoY improvement in the cash conversion cycle and active inventory management. Capital allocation remained balanced, with ongoing dividends, share repurchases, and strategic CapEx investments in Penang and production capacity to support new program ramps.
- Medical and ACNC Outperformance: These sectors delivered double-digit growth and drove Q4 margin resilience, validating the company’s sector focus.
- Semi-Cap Inflection Delayed but Visible: While Q4 was soft, management now expects recovery to begin earlier in 2026, with customer orders accelerating.
- Cash Flow and Working Capital Execution: Inventory turns improved to 5.2, and the cash conversion cycle dropped to 67 days, unlocking capital for growth initiatives.
The quarter’s results reinforce BHE’s ability to flex its portfolio and cost base to maintain profitability, even as end-market demand remains uneven. The business model’s focus on higher-value, complex segments is delivering margin durability and positioning the company for multi-segment growth as semi-cap and industrial recoveries materialize.
Executive Commentary
"We target five core high-value markets by focusing on complex, high-mix opportunities that suit our strengths. We avoid commoditized markets and are pursuing an ODM approach, building vanilla solutions. If you look at our business today, you'll see a very evenly balanced portfolio, each sector representing long-term growth opportunities where we believe we can excel and differentiate."
Jeff Benck, Chief Executive Officer
"Our Q4 revenue continued the sequential improvements that we saw throughout the year, exiting at a little over $700 million, which was up 7% versus Q4 2024. At the same time, fourth quarter gross margin of 10.6% continued our multi-quarter trend of 10% or greater performance. Coupled with expense management, this translated into sequential improvements in operating margin and EPS performance throughout the year, with fourth quarter and full year EPS growing greater than twice the rate of revenue growth."
Brian [Last Name], Chief Financial Officer
Strategic Positioning
1. Sector Diversification and Mix Management
BHE’s portfolio strategy is built around balancing exposure across five sectors, deliberately reducing reliance on any single vertical. This quarter, medical and ACNC provided the growth offset as semi-cap and industrial lagged, demonstrating the value of this approach. The company’s avoidance of commoditized markets and focus on high-mix, complex assemblies supports sustainable margin performance.
2. Capital Allocation and Capacity Investment
Free cash flow strength and a net cash positive balance sheet enabled BHE to invest in new capacity, including the fourth Penang building, and production equipment aligned to new program wins. The company remains committed to shareholder returns via dividends and buybacks, while scaling CapEx to support growth in space, medtech, and AI infrastructure.
3. Operating Leverage and Cost Discipline
Operating expense management and working capital efficiency are unlocking margin leverage, with SG&A growth lagging revenue expansion. Inventory turns and cash cycle improvements are freeing up capital for reinvestment and reducing risk from demand volatility.
4. Strategic Customer Wins and Bookings Momentum
Bookings momentum across space, medtech, and enterprise AI positions BHE for above-market growth, as these wins ramp into revenue over the next 12 to 24 months. Competitive takeaways and new program launches are broadening the company’s customer base and deepening relationships in high-growth verticals.
5. Leadership Transition and Strategic Continuity
The CEO transition from Jeff Benck to David [Last Name] is framed as a continuation of the current strategy, with no change to capital allocation priorities or sector focus. The incoming CEO’s emphasis on operational execution and sector momentum signals a steady hand as the company enters its next phase.
Key Considerations
This quarter’s results underscore BHE’s ability to manage through sector cyclicality, while positioning for recovery and expansion in its most attractive markets. The following considerations will shape investor focus in the coming quarters:
- Medical and ACNC Growth Sustainability: Continued double-digit growth in these segments is critical for margin and revenue momentum as semi-cap recovers.
- Semi-Cap Recovery Slope and Timing: Management expects a pickup earlier in 2026, but the pace and magnitude of recovery remain dependent on customer order flows and macro conditions.
- CapEx Ramp and Execution Risk: Investments in Penang and new equipment must translate into program wins and revenue conversion, particularly in AI and space applications.
- Margin Resilience Amid Mix Shifts: The company’s ability to maintain or expand gross and operating margins as the sector mix evolves will be a key watchpoint.
Risks
BHE faces ongoing risks from sector cyclicality, especially in semi-cap and industrial, where macro volatility and customer order timing can disrupt growth. The company’s reliance on new program ramps in medical, space, and AI infrastructure introduces execution risk, as delays or cancellations could impact revenue and margin. Additionally, global supply chain uncertainties and geopolitical pressures, particularly around China import restrictions, remain external threats to the outlook.
Forward Outlook
For Q1 2026, BHE guided to:
- Revenue of $655 to $695 million, up 7% YoY at midpoint
- Non-GAAP gross margin of 10 to 10.4%
- Non-GAAP operating margin of 4.7 to 4.9%
- EPS of $0.53 to $0.59
For full-year 2026, management reaffirmed mid-single-digit growth guidance, with upside potential as customer demand visibility improves. Capital expenditures are expected to rise to 2 to 2.5% of revenue, supporting Penang expansion and new program investments.
- Medical and ACNC expected to sustain double-digit growth into H1
- Semi-cap recovery now projected to begin earlier in 2026, with ramp clarity improving over the next quarter
Takeaways
BHE’s Q4 and full-year performance demonstrate a business model built for resilience and operational leverage, with sector rotation cushioning volatility and new program wins driving future upside.
- Sector Mix Shift: Medical and ACNC are now key growth engines, validating the company’s focus on complex, high-mix markets and supporting margin durability.
- Operational Leverage: Cost discipline and working capital efficiency are translating into margin expansion and cash flow, positioning BHE to capitalize on sector recoveries.
- 2026 Watchpoints: Investors should monitor the timing and slope of semi-cap recovery, the sustainability of medical and ACNC growth, and the execution of capacity expansion in Penang and program ramps in space and AI.
Conclusion
BHE enters 2026 with momentum in its most attractive segments, a strengthened balance sheet, and a clear path to operational leverage. The business model’s pivot toward higher-value, less commoditized markets is delivering results, but execution on new program ramps and sector recoveries will be critical to sustaining growth and margin expansion in the coming year.
Industry Read-Through
BHE’s results and commentary provide a read-through for the broader EMS and contract manufacturing sector: sector diversification and high-mix, complex program focus are increasingly essential for margin stability as cyclicality persists in legacy verticals like semi-cap and industrial. The acceleration of bookings in medtech, space, and AI infrastructure signals where demand is shifting, while cash discipline and operational leverage are separating resilient players from those exposed to commoditization. Other EMS and manufacturing peers should heed the importance of portfolio balance, customer program wins, and execution on capacity investments as the industry navigates macro and sector-specific inflections in 2026.